This year, the Chinese government implemented its domestic-international dual circulation strategy: the country wants to strengthen domestic demand and be less dependent on imports. This policy has huge implications for the life sciences, both in China and abroad. Local policies shall support the establishment of the entire value chain in China, and Chinese companies obtain subsidies for overseas market development. As a result, Swiss startups might benefit from the growing interest of Chinese venture capital funds. On the other hand, multinational companies will face increased competition from domestic firms. Lukas Zuest, Counsel and Head China Desk at the Swiss law firm Vischer, talked about the impact of the domestic-international dual circulation policy on the life science industry in both countries at the online edition of the Swiss Chinese Life Sciences Forum. The fourth edition of the event, organized in collaboration with VISCHER, the Swiss Chinese Chamber of Commerce and Basel Area Business & Innovation, attracted a diverse audience, not only from Switzerland and China, but also from many other European countries and even from India.